NIKKEI 225
38,638.62 +5.60 (+0.01%) HANG SENG
17,991.93 -343.39 (-1.87%) CRUDE OIL
82.34 +0.17 (+0.21%) GOLD FUTURES
2,376.00 +7.00 (+0.30%) DOW
39,134.76 +299.90 (+0.77%) Bitcoin GBP
50,936.05 -614.85 (-1.19%)
LLY Sep 2024 450.000 call
| Previous close | 416.05 |
| Open | 416.05 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 450.00 |
| Expiry date | 2024-09-20 |
| Day's range | 416.05 - 416.05 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
ZacksEli Lilly (LLY) Registers a Bigger Fall Than the Market: Important Facts to Note
The latest trading day saw Eli Lilly (LLY) settling at $885.99, representing a -0.61% change from its previous close.
Barrons.comObesity-Drug Developers Look at What’s Next for a $100 Billion Market
Oppenheimer analyst Jay Olson spent several days last week listening as companies such as Eli Lilly discussed how to improve on blockbusters like Zepbound and Novo Nordisk’s Wegovy.
Associated Press FinanceWHO and Eli Lilly caution patients against falling for fake versions of popular weight-loss drugs
The World Health Organization and drugmaker Eli Lilly and Co. are warning people to be wary of fake versions of popular weight-loss and diabetes medicines. WHO said Thursday that it has fielded several reports of fake semaglutide — the active ingredient in Novo Nordisk’s Wegovy and Ozempic — in all geographic regions of the world since 2022. Lilly said in an open letter that it was “deeply concerned” about growing online sales and social media posts involving phony or compounded versions of tirzepatide, the active ingredient behind its drugs Mounjaro and Zepbound.
